XPXiomara A. Perez

Xiomara A. Perez

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xiomara A. Perez has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The striatal cholinergic system in l-dopa-induced dyskinesias

    by X. A. Perez, T. Bordia, M. Quik

    Cholinergic signaling plays a key role in regulating striatal function. The principal source of acetylcholine in the striatum is the cholinergic interneurons which, although low in number, densely arborize to modulate striatal neurotransmission. This modulation occurs via strategically positioned nicotinic and muscarinic acetylcholine receptors that influence striatal dopamine, GABA and other neurotransmitter release. Cholinergic interneurons integrate multiple striatal synaptic inputs and outputs to regulate motor activity under normal physiological conditions. Consequently, an imbalance between these systems is associated with basal ganglia disorders. Here, we provide an overview of how striatal cholinergic interneurons modulate striatal activity under normal and pathological conditions. Numerous studies show that nigrostriatal damage such as that occurs with Parkinson’s disease affects cholinergic receptor-mediated striatal activity. This altered cholinergic signaling is an important contributor to Parkinson’s disease as well as to the dyskinesias that develop with l-dopa therapy, the gold standard for treatment. Indeed, multiple preclinical studies show that cholinergic receptor drugs may be beneficial for the treatment of l-dopa-induced dyskinesias. In this review, we discuss the evidence indicating that therapeutic modulation of the cholinergic system, particularly targeting of nicotinic cholinergic receptors, may offer a novel approach to manage this debilitating side effect of dopamine replacement therapy for Parkinson’s disease.


  • Striatal D1 medium spiny neuron activation induces dyskinesias in parkinsonian mice

    by Xiomara A. Perez, Danhui Zhang, Tanuja Bordia, Maryka Quik

    Background: Dyskinesias are a disabling motor complication that arises with prolonged l‐dopa treatment. Studies using D1 receptor drugs and genetically modified mice suggest that medium spiny neurons expressing D1 receptors play a primary role in l‐dopa–induced dyskinesias. However, the specific role of these neurons in dyskinesias is not fully understood.Methods: We used optogenetics, which allows for precise modulation of select neurons in vivo, to investigate whether striatal D1‐expressing medium spiny neuron activity regulates abnormal involuntary movements or dyskinesia in parkinsonian mice. D1‐cre mice unilaterally lesioned with 6‐hydroxydopamine received striatal injections of cre‐dependent channelrhodopsin2 virus or control virus. After stable virus expression, the effect of optical stimulation on dyskinesia was tested in l‐dopa–naïve and l‐dopa–primed mice.Results: Single‐pulse and burst‐optical stimulation of D1‐expressing medium spiny neurons induced dyskinesias in l‐dopa–naïve channelrhodopsin2 mice. In stably dyskinetic mice, l‐dopa injection induced dyskinesia to a similar or somewhat greater extent than optical stimulation. Combined l‐dopa administration and stimulation resulted in an additive increase in dyskinesias, indicating that other mechanisms also contribute. Molecular studies indicate that changes in extracellular signal‐regulated kinase phosphorylation in D1‐expressing medium spiny neurons are involved. Optical stimulation did not ameliorate parkinsonism in l‐dopa–naïve mice. However, it improved parkinsonism in l‐dopa–primed mice to a similar extent as l‐dopa administration. None of the stimulation paradigms enhanced dyskinesia or modified parkinsonism in l‐dopa–naïve or l‐dopa–primed control virus mice.Conclusion: The data provide direct evidence that striatal D1‐expressing medium spiny neuron stimulation is sufficient to induce dyskinesias and contributes to the regulation of motor control. © 2017 International Parkinson and Movement Disorder Society


  • Preclinical Evidence for a Role of the Nicotinic Cholinergic System in Parkinson’s Disease

    by Xiomara A. Perez

    One of the primary deficits in Parkinson’s disease (PD) is the loss of dopaminergic neurons in the substantia nigra pars compacta which leads to striatal dopaminergic deficits that underlie the motor symptoms associated with the disease. A plethora of animal models have been developed over the years to uncover the molecular alterations that lead to PD development. These models have provided valuable information on neurotransmitter pathways and mechanisms involved. One such a system is the nicotinic cholinergic system. Numerous studies show that nigrostriatal damage affects nicotinic receptor-mediated dopaminergic signaling; therefore therapeutic modulation of the nicotinic cholinergic system may offer a novel approach to manage PD. In fact, there is evidence showing that nicotinic receptor drugs may be useful as neuroprotective agents to prevent Parkinson’s disease progression. Additional preclinical studies also show that nicotinic receptor drugs may be beneficial for the treatment of L-dopa induced dyskinesias. Here, we review preclinical findings supporting the idea that nicotinic receptors are valuable therapeutic targets for PD.


  • Open Access

    Varenicline enhances dopamine release facilitation more than nicotine after long‐term nicotine treatment and withdrawal

    by Xiomara A. Perez, Taline V. Khroyan, J. Michael McIntosh, Maryka Quik

    An important factor contributing to the high relapse rates among smokers is nicotine withdrawal symptoms. Multiple studies suggest that decreased dopamine release in nucleus accumbens plays a key role in withdrawal. However, recent reports showed that long‐term nicotine exposure itself also decreases accumbal dopamine release, suggesting that additional mechanisms are involved in withdrawal. Here, we used real‐time cyclic voltammetry in brain slices containing the nucleus accumbens to further elucidate the changes in dopamine release linked to nicotine withdrawal. Rats received vehicle or nicotine via the drinking water for 2–3 months. Studies assessing the expression of somatic signs in vehicle‐treated, nicotine‐treated, and 24‐h nicotine withdrawn rats showed that nicotine withdrawal led to a significant increase in somatic signs. Subsequent voltammetry studies showed that long‐term nicotine decreased single‐pulse‐stimulated dopamine release via an interaction at α6β2* receptors. Nicotine withdrawal led to a partial recovery in α6β2* receptor‐mediated release. In addition, long‐term nicotine treatment alone increased dopamine release paired‐pulse ratios and this was partially reversed with nicotine removal. We then evaluated the effect of bath‐applied nicotine and varenicline on dopamine release. Nicotine and varenicline both decreased single‐pulse‐stimulated release in vehicle‐treated, nicotine‐treated, and nicotine withdrawn rats. However, bath‐applied varenicline increased paired‐pulse ratios to a greater extent than nicotine during long‐term nicotine treatment and after its withdrawal. Altogether these data suggest that nicotine withdrawal is associated with a partial restoration of dopamine release measures to control levels and that varenicline's differential modulation of dopamine release may contribute to its mechanism of action.


  • Open Access

    Long‐term nicotine treatment down‐regulates α6β2* nicotinic receptor expression and function in nucleus accumbens

    by Xiomara A. Perez, J.Michael McIntosh, Maryka Quik

    Long‐term nicotine exposure induces alterations in dopamine transmission in nucleus accumbens that sustain the reinforcing effects of smoking. One approach to understand the adaptive changes that arise involves measurement of endogenous dopamine release using voltammetry. We therefore treated rats for 2–3 months with nicotine and examined alterations in nAChR subtype expression and electrically evoked dopamine release in rat nucleus accumbens shell, a region key in addiction. Long‐term nicotine treatment selectively decreased stimulated α6β2* nAChR‐mediated dopamine release compared with vehicle‐treated rats. It also reduced α6β2* nAChRs, suggesting the receptor decline may contribute to the functional loss. This decreased response in release after chronic nicotine treatment was still partially sensitive to the agonist nicotine. Studies with an acetylcholinesterase inhibitor demonstrated that the response was also sensitive to increased endogenous acetylcholine. However, unlike the agonists, nAChR antagonists decreased dopamine release only in vehicle‐ but not nicotine‐treated rats. As antagonists function by blocking the action of acetylcholine, their ineffectiveness suggests that reduced acetylcholine levels partly underlie the dampened α6β2* nAChR‐mediated function in nicotine‐treated rats. As long‐term nicotine modifies dopamine release by decreasing α6β2* nAChRs and their function, these data suggest that interventions that target this subtype may be useful for treating nicotine dependence. image Long‐term nicotine treatment decreases dopamine (DA) transmission in the mesolimbic dopaminergic system. Our data suggest this may involve a decrease in α6β2* nicotinic receptor expression and function. These changes may play a key role in nicotine reward and dependence.


  • Open Access

    Cortical nNOS neurons co-express the NK1 receptor and are depolarized by Substance P in multiple mammalian species

    by Lars Dittrich, Jaime E. Heiss, Deepti R. Warrier, Xiomara A. Perez, Maryka Quik, Thomas S. Kilduff

    We have previously demonstrated that Type I neuronal nitric oxide synthase (nNOS)-expressing neurons are sleep-active in the cortex of mice, rats, and hamsters. These neurons are known to be GABAergic, to express Neuropeptide Y (NPY) and, in rats, to co-express the Substance P (SP) receptor NK1, suggesting a possible role for SP in sleep/wake regulation. To evaluate the degree of co-expression of nNOS and NK1 in the cortex among mammals, we used double immunofluorescence for nNOS and NK1 and determined the anatomical distribution in mouse, rat, and squirrel monkey cortex. Type I nNOS neurons co-expressed NK1 in all three species although the anatomical distribution within the cortex was species-specific. We then performed in vitro patch clamp recordings in cortical neurons in mouse and rat slices using the SP conjugate tetramethylrhodamine-SP (TMR-SP) to identify NK1-expressing cells and evaluated the effects of SP on these neurons. Bath application of SP (0.03–1 μM) resulted in a sustained increase in firing rate of these neurons; depolarization persisted in the presence of tetrodotoxin. These results suggest a conserved role for SP in the regulation of cortical sleep-active neurons in mammals.